TITLE

NEUROBIOLOGICAL TECHNOLOGIES SIGNS VIPRINEX PACTS

PUB. DATE
August 2005
SOURCE
Worldwide Biotech;Aug2005, Vol. 17 Issue 8, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the license agreements of Neurobiological Technologies Inc. (NTI) with Nordmark Arzneimittel GmbH & Co. KG, and Baxter Pharmaceutical Solutions LLC to manufacture, fill and package Viprinex for the phase III of NTI in acute ischemic stroke. Terms of the agreement; Comment of Stephen J. Petti, vice president of product development at NTI; Background information on the companies.
ACCESSION #
17732357

 

Related Articles

  • Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction. Pitt, B.; White, H.; Nicolau, J. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p14 

    The article reports on a study to determine whether adjunctive treatment with eplerenone can decrease morbidity and mortality better than placebo in patients with acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and heart failure. A randomized placebo...

  • ECHO: Potential research participants' views regarding researcher and institutional financial conflicts of interest. Kim, S. Y. H.; R. W. Millard; P. Nisbet; C. Cox; E. D. Caine // Journal of Epidemiology & Community Health;Aug2004, Vol. 58 Issue 8, p673 

    The researchers surveyed potential research participants over the Internet, using the Harris Interactive Chronic Illness Database. A potential research participant was defined by: self report of diagnosis by a health care professional and willingness to participate in clinical trials. Email...

  • Aspirin + clopidogrel therapy: How does your care compare to the evidence? Simmons, B. Brent; Salzman, Brooke E. // Journal of Family Practice;Jan2008, Vol. 57 Issue 1, p26 

    The article focuses on the latest trials and recommendations on dual antiplatelet therapy as they pertain to acute coronary syndrome (ACS), coronary stents, stroke, and the primary prevention and secondary prevention of distant cardiovascular events. One of the trials cited is The Clopidogrel in...

  • Multidimensional interventions for prevention following ACS encouraging.  // Cardiology Today;Jul2008, Vol. 11 Issue 7, p34 

    The article discusses research being done on the effect of multidimensional interventions on acute coronary syndrome. It references a study by researchers from Canada and Switzerland published in a 2008 issue of "Circulation." Based on a systematic review and meta-analysis of 14 controlled...

  • Medikamente freisetzende Stents im Vergleich zu Bypass-Operationen bei koronarer Herzkrankheit. Gorenoi, Vitali; Dintsios, Charalabos-Markos; Schönermark, Matthias P.; Hagen, Anja // GMS Health Technology Assessment;2009, Vol. 5, p1 

    Background Coronary artery bypass graft (CABG) and percutaneous revascularisations with implantation of drug-eluting stents (DES) are important treatment methods in coronary heart disease (CHD). Research questions The evaluation addresses questions on medical efficacy, health economic parameters...

  • Review: Routine invasive management after unstable angina or non--ST-segment elevation MI reduces risk for death or MI.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p69 

    This article presents information on a clinical study according to which routine invasive management after unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) reduces risk for death or MI. The study explored whether in patients with unstable angina or NSTEMI, initial...

  • Risk scores are of limited benefit to CHD patients.  // GP: General Practitioner;6/3/2005, p17 

    This article reports that according to a new study, relying on the Framingham risk score to identify patients with coronary heart disease (CHD) may not be beneficial. Peter Brindle, a general practitioner in Bristol, England, who co-wrote the research, said that of 126 studies of the accuracy of...

  • He Who Pays the Piper Calls the Tune: The Role of the Industry Sponsor in Acute Stroke Trials. Bozik, Michael // European Neurology;2003, Vol. 49 Issue 2, p128 

    Ischemic stroke remains a complex neurobiological and clinical disease, and stroke drug development remains time consuming and costly. In addressing these challenges, the pharmaceutical industry has a principal responsibility to ensure that the acute stroke trials it sponsors are ethically...

  • Commentary. Moyer, Carey D.; Berger, Peter B. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p14 

    The article comments on a study by B. Pitt and colleagues to determine whether adjunctive treatment with eplerenone can decrease morbidity and mortality better than placebo in patients with acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and heart failure. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics